Redseywe's good news again! Phase III clinical lying is effective in patients with COVID-19!

MATH ( UPI) -- The latest clinical trial results from Gilead, the maker of the antiviral drug Redseve, show more good news for the drug's efficacyGilead said recently that in a trial involving multiple patients, Redsewe had a lower risk of death compared to standard treatment sourcing improved rehabilitationThe study also showed that only patients who received Redsiwe's treatment recovered on the first day of treatment and received standard treatmentPhoto Source: The results of the study, published recently, were a comparative analysis of patients treated in the Redsewee phase study and those who were not involved in the study and received standard treatmentGilead reported that patients treated with Redseve had a mortality rate on the day of day and those who were not treatedSome patients take the drug better than othersThe researchers found that black patients were particularly better off than those under the age of olderPatients who do not use ventilators have more benefits from indoor air or low-flow oxygen than those who use ventilatorsThese results were published at virtual meetings and were not published in peer-reviewed journalsGilead also stressed that these findings should be considered preliminary and need to be identified in prospective clinical trialsGilead said a recent analysis of its "sympathetic use program" showed that among children, pregnant women and postnatal women, patients recovered on the first day and received treatment for RedseweTo learn more about these patients, Gilead recently announced a global, open-label phase trial to assess Redsewe's safety, tolerance and therapeutic effectiveness in patients with age and is collaborating on a study involving pregnant women() References: